Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03198117 | Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small… | N/A | terminated | Jun 23, 2017 | Qidong Gaitianli Medicines Co., Ltd | Difficulty in patient recruitment | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT03460678 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of… | Phase 4 | terminated | Mar 9, 2018 | Hikma Pharmaceuticals LLC | Difficulty recruiting | Enrollment / accrual |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab,…(iTRAP) | Phase 1 | withdrawn | Apr 13, 2018 | Queen Mary University of London | Funder and IMP manufacturer withdrew support | Drug supply |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared… | Phase 1 | terminated | Jun 11, 2015 | Novartis Pharmaceuticals | Major challenge for enrollment of participants. | Enrollment / accrual |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For… | Phase 2 | terminated | Jun 11, 2015 | howard safran | Lack of accrual | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Phase 2 | terminated | Apr 17, 2014 | Heat Biologics | Sponsor Decision; strategic - based on changing treatment landscape | Sponsor / business decision |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell… | Phase 1 | withdrawn | Mar 28, 2013 | Acrotech Biopharma Inc. | not stated | Not stated |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
| NCT03872440 | PDX Models From EGFR Mutant Tumors | — | withdrawn | Mar 13, 2019 | Addario Lung Cancer Medical Institute | Did not meet the expected enrollment rate. | Enrollment / accrual |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung… | Phase 1 | terminated | Aug 8, 2013 | Central European Cooperative Oncology Group | poor accrual | Enrollment / accrual |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to… | Phase 1 | terminated | Dec 18, 2013 | Eli Lilly and Company | This trial was terminated early based on the lack of sufficient clinical efficacy observed. | Efficacy / futility |
| NCT03564054 | Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With… | N/A | terminated | Jun 20, 2018 | University of Florida | slow accrual | Enrollment / accrual |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | Early Phase 1 | terminated | Aug 10, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02501707 | Echocardiography for RILI Prediction | — | terminated | Jul 17, 2015 | Maastricht Radiation Oncology | The study is prematurely terminated due to bad inclusion and the fact that examinations are already… | Other (stated, no rule matched) |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell… | Phase 2 | terminated | Jul 28, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure - investigator left the National Institutes of Health. | Investigator |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | Phase 2 | terminated | May 12, 2016 | Dana-Farber Cancer Institute | Terminated due to Osimertinib approval | Other (stated, no rule matched) |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally… | Phase 3 | withdrawn | May 18, 2018 | Novartis Pharmaceuticals | Decision by Sponsor not to continue with the trial. | Other (stated, no rule matched) |
| NCT02356991 | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung… | Phase 2 | suspended | Feb 6, 2015 | Jiangsu HengRui Medicine Co., Ltd. | sponsor decides to suspend this trial | Other (stated, no rule matched) |
| NCT02538432 | Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid… | Phase 2 | withdrawn | Sep 2, 2015 | University of Maryland, Baltimore | PI No Longer at University of Maryland. Now at Fox Chase | Other (stated, no rule matched) |
| NCT03272971 | Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors | N/A | terminated | Sep 6, 2017 | Broncus Medical Inc | Lack of enrollment | Enrollment / accrual |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small… | Phase 1 | terminated | May 19, 2015 | ACEA Therapeutics, Inc. | not stated | Not stated |
| NCT03311672 | T-Cell PET Imaging With [18F]F-AraG in Lung Cancer | Phase 2 | withdrawn | Oct 17, 2017 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced… | Phase 1 / Phase 2 | withdrawn | Jan 8, 2014 | University of Maryland, Baltimore | PI has left the study institution. | Other (stated, no rule matched) |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC… | Phase 1 / Phase 2 | terminated | Sep 30, 2016 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | Phase 1 | withdrawn | Jun 11, 2019 | Muhammad Furqan | Sponsor decision to withdraw | Sponsor / business decision |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02002052 | Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized,…(FLAIR) | Phase 2 | terminated | Dec 5, 2013 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Insufficient accrual | Enrollment / accrual |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With… | Phase 1 | terminated | Mar 17, 2016 | Novartis Pharmaceuticals | considering the limited clinical activity observed with LTT462, the decision was made to not open… | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild…(EGF) | Phase 3 | terminated | Jul 11, 2014 | Bioven Europe | Sponsor decision based on slow recruitment and new emerging drug combinations | Enrollment / accrual |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune… | N/A | terminated | Oct 18, 2016 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02132884 | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV… | N/A | terminated | May 7, 2014 | Fox Chase Cancer Center | Feasibility | Other (stated, no rule matched) |
| NCT03130829 | To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving… | N/A | withdrawn | Apr 27, 2017 | Hi-Q Marine Biotech International, Ltd. | target population is insufficient | Other (stated, no rule matched) |
| NCT03479294 | Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients… | — | terminated | Mar 27, 2018 | West China Hospital | Because of the difficulty of research operation, we changed to another research design. | Other (stated, no rule matched) |
| NCT02054819 | Treating NSCLC Minimal Stage IV With Curative Intent | Phase 2 | terminated | Feb 4, 2014 | Leo W. Jenkins Cancer Center | Didn't meet accrual goal, change in standard of care. | Enrollment / accrual |
| NCT01374100 | Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer… | N/A | terminated | Jun 15, 2011 | McGill University | Slow accrual, and revised power calculation for primary end-points | Enrollment / accrual |
| NCT02200354 | The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab | Phase 2 | terminated | Jul 25, 2014 | Kobe City General Hospital | inclusion speed | Other (stated, no rule matched) |
| NCT02322281 | TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus… | Phase 3 | terminated | Dec 23, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC | Other (stated, no rule matched) |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer(NSCLC) | Phase 1 | withdrawn | Jan 24, 2017 | Benjamin Movsas, M.D. | No participants were enrolled | Enrollment / accrual |
| NCT01822496 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients… | Phase 2 | terminated | Apr 2, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 9, 2020source: clinicaltrials